2026/04/09 by Stephan A. Ramos, Preksha Bhagchandani, Diego M. Burgos +7 · 1 voice
Medicine · #Hematopoietic Stem Cell Transplantation #Mesenchymal stem cell research #Pancreatic function and diabetes
paper · pdf · doi:10.1172/jci.insight.194491
openalex created_date 2025/10/10 · openalex publication_date 2026/04/09 · openalex updated_date 2026/07/27
Mixed hematopoietic chimerism after hematopoietic cell transplantation (HCT) can modulate the immune system and induce tolerance to allogeneic tissues. However, bone marrow conditioning-related toxicities preclude wider adoption of HCT for transplant allotolerance. We sought agents that reduced conditioning intensity, while promoting durable mixed chimerism after HCT across complete MHC mismatch in diabetic mice, permitting islet allotransplantation and diabetes reversal. We systematically tested baricitinib (JAK1/2 inhibitor), venetoclax (Bcl-2 inhibitor), and CD47 antibody, agents in current clinical use, and quantified hematopoietic chimerism after HCT. Combined with CD117 antibody, transient T cell depletion, and just 10 centigray total body irradiation, these agents enabled durable mixed chimerism and matching alloislet tolerance to cure diabetes without evidence of graft-versus-host disease. Thus, we have developed a conditioning regimen to promote allogeneic mixed hematopoietic chimerism and transplanted islet allotolerance that minimizes conditioning radiation and cures diabetes.